Table 1.
Characteristics of included studies.
| Study | Country | Sample size (male/female) | Mean age (yr) | Baseline TPOAb levels (mean ± SD) | Baseline TgAb levels (mean ± SD) | Study design | Outcomes | Duration (mo) |
|---|---|---|---|---|---|---|---|---|
| Krysiak A 2019[10] | Poland | 17 (17/0) | 34 | 878 ± 286 | 783 ± 312 | Selenomethionine (200 μg/d) vs pretreatment | TPOAb, TgAb, TSH, fT4, fT3 | 6 |
| Krysiak B 2018[11] | Poland | 22 (0/22) | 48 | 892 ± 247 | 810 ± 301 | Selenomethionine (200 μg/d) vs pretreatment |
TPOAb, TgAb, TSH, ft3 | 6 |
| Nordio A 2017[12] | Italy | 84 (10/74) | 40.9 | 820.13 ± 513.99 | 415.43 ± 275.89 | l-selenomethionine (selenium 83μg/d) vs pretreatment | TPOAb, TgAb, TSH, fT4, fT3 | 6 |
| Nordio B 2017[13] | Italy | 87 (8/79) | 42.3 | 720.67 ± 52.39 | 344.96 ± 23.77 | Myo-inositol 600mg/d plus selenium 83 μg/d Vs pretreatment | TPOAb, TgAb, TSH, fT4, fT3 | 6 |
| Krysiak C 2012[14] | Poland | 73 (0/73) | 40.5 | 1682 ± 395 | 1720 ± 498 | selenomethionine (200 μg/d) vs placebo |
TPOAb, TgAb, TSH, fT4, fT3 | 3, 6 |
| Onal 2012[15] | Turkey | 23 (7/16) | 12.3 | 210 ± 349 | 272 ± 712 | 50 μg l-selenomethionine vs pretreatment |
TPOAb, TgAb, TSH, fT4 | 3 |
| Karanikas 2008[16] | Austria | 36 (0/36) | 47 | 524 ± 452 | NA | Selenomethionine (200 μg/d) vs placebo |
TPOAb, TSH, fT4, Se | 3 |
fT3 = triiodothyronine, fT4 = thyroxine, NA = not available, SD = standard deviations, TgAb = thyroglobulin antibodies, TPOAb = thyroid peroxidase antibodies, TSH = thyrotropin.